.avif)
LDH Test - Melanoma Biomarker
LDH (lactate dehydrogenase) measures an enzyme released with tissue damage and can flag liver disease, heart injury (including heart attack), hemolysis, muscle injury and some cancers. Catching abnormal LDH early helps prompt diagnosis and treatment, potentially avoiding severe complications.
TERT Promoter Test - Melanoma Biomarker
A TERT promoter test detects mutations that turn on telomerase, flagging tumor presence and aggressiveness. It can help detect and monitor cancers (eg, glioma, melanoma, bladder, thyroid) earlier so treatment can begin sooner and reduce the risk of delayed diagnosis and worse outcomes.
KIT Gene Test - Melanoma Biomarker
Screening the KIT gene detects inherited or tumor-acquired KIT (c‑KIT) mutations that signal increased risk or presence of KIT-driven conditions. Identifying these variants enables earlier monitoring and targeted treatment decisions that can help catch or manage gastrointestinal stromal tumors, mast cell disorders, and some melanomas before they progress.
NRAS Mutation Test - Melanoma Biomarker
This NRAS mutation test detects changes in the NRAS gene commonly found in melanoma, colorectal cancer and certain blood cancers. Knowing NRAS status can guide treatment selection and monitoring, helping clinicians choose more effective, targeted therapies sooner and avoid ineffective or delayed treatments.
BRAF V600E Mutation Test - Melanoma Biomarker
Detects the BRAF V600E genetic mutation found in cancers like melanoma, papillary thyroid cancer, colorectal cancer and hairy cell leukemia to guide targeted therapy and prognosis. Knowing your BRAF V600E status can help avoid ineffective treatments and enable earlier, personalized therapy that reduces the risk of cancer progression and metastasis.
.svg)
